SOX2 and sarcoma: Our findings that SOX2 is highly expressed in DSRCT, associated with worse survival in sarcoma patients, and enriched in metastatic DSRCT tumors suggest the clinical relevance of DSRCT subpopulations with high SOX2 expression and the importance of a model that enables their investigation.